Concord Biotech has announced its financial results for the first quarter of Fiscal Year 2027 (Q1FY27). The company reported a significant 26% year-on-year increase in revenue, reaching ₹257.5 crore. EBITDA saw a substantial rise of 34% to ₹82.4 crore, while Profit After Tax (PAT) grew by 31% to ₹57.7 crore. Gross Profit Margin improved to 78.9%, and EBITDA Margin stood at 32.0%.
Concord Biotech Reports Strong Q1 FY27 Financial Performance
Concord Biotech Limited has released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company demonstrated robust growth across key financial metrics, signaling a positive start to the fiscal year.
Key Financial Highlights (Q1 FY27 vs. Q1 FY26)
Revenue Growth
Revenue from Operations witnessed a significant increase of 26.2%, rising from ₹204 crore in Q1 FY26 to ₹257 crore in Q1 FY27. This broad-based growth was attributed to performance across all product categories and geographies, with export revenue surging by an impressive 46% year-on-year.
Profitability Metrics
Gross Profit grew by 27.9% to ₹203 crore, and the Gross Profit Margin improved by 100 basis points to 78.9% from 77.9% in the prior year quarter. EBITDA increased by 34.2% to ₹82 crore, with the EBITDA Margin expanding to 32.0% (up 190 bps). After accounting for depreciation and other expenses, EBIT rose by 34.6% to ₹77 crore. Consequently, Profit After Tax (PAT) saw a substantial growth of 31.0%, reaching ₹58 crore, with the PAT Margin at 22.4%, an improvement of 80 basis points.
Segment Revenue Split
The company’s revenue split shows a strong performance in the API segment, which grew by 42% to ₹218.9 crore. While the Formulation segment saw a decline of 23% to ₹38.6 crore, the combined Total Revenue reflects the overall positive trend. Domestic Revenue increased by 12% to ₹135.8 crore, and Exports Revenue saw a significant jump of 46% to ₹121.7 crore, contributing substantially to the total revenue growth.
Management Commentary
Commenting on the performance, Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer, stated, “We are pleased to report a strong revenue growth of 26% year-on-year in Q1FY27, driven by broad-based performance across product categories and geographies.” He highlighted the increase in wallet share from existing customers, expansion of the customer base, and successful regulatory inspections by ANVISA, PPB of Kenya, and NDA of Uganda as key drivers for sustained momentum.
Source: BSE
